Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
induced pluripotent stem cell-derived limbal stem cells
- Development stage
- Unknown
- Lead developer
- Osaka University
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Ophthalmic
01
Overview
Induced pluripotent stem cell-derived limbal stem cells, often referred to as induced pluripotent stem cell-derived corneal epithelial sheets (iCEPS), are an experimental cell therapy developed by researchers at Osaka University for the treatment of limbal stem cell deficiency (LSCD). LSCD is a condition characterized by the loss of stem cells at the limbus, which leads to corneal opacity and blindness. This therapeutic approach involves the differentiation of human induced pluripotent stem cells (iPSCs) into corneal epithelial cells, which are then cultured into transplantable sheets. By grafting these sheets onto the patient's eye, the therapy aims to restore the corneal surface and vision. This modality provides a potentially unlimited source of cells, addressing the limitations of donor tissue scarcity and reducing the risk of rejection if autologous iPSCs are utilized.
- Other names
- induced pluripotent stem cell-derived corneal epithelial sheetsiPSC-derived limbal stem cellsiPSC-derived corneal epithelial cells
Beyond the preview
Go deeper on induced pluripotent stem cell-derived limbal stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on induced pluripotent stem cell-derived limbal stem cells.